EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.

EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that causes progressive paralysis due to motor neuron death. Several lines of published evidence suggested that inhibition of epidermal growth factor receptor (EGFR) signaling might protect neurons from degeneration. To test th...

Full description

Bibliographic Details
Main Authors:	Claire E Le Pichon, Sara L Dominguez, Hilda Solanoy, Hai Ngu, Nicholas Lewin-Koh, Mark Chen, Jeffrey Eastham-Anderson, Ryan Watts, Kimberly Scearce-Levie
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3637182?pdf=render

Similar Items

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020-03-01)

Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset
by: Kazuto Nishio, MD, PhD, et al.
Published: (2021-06-01)

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
by: Jeng-Sen Tseng, et al.
Published: (2014-01-01)

Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation
by: S. V. Orlov, et al.
Published: (2019-06-01)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky.
by: Kara L Larson, et al.
Published: (2020-01-01)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
by: Chandra Bartholomeusz, Fumiyuki Yamasaki, Hitomi Saso, Kaoru Kurisu, Gabriel N. Hortobagyi, Naoto T. Ueno
Published: (2011-01-01)

Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
by: J. Ryan Petrulli, et al.
Published: (2013-12-01)

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
by: Florent Baty, et al.
Published: (2013-01-01)

The ways of erlotinib resistance overcoming in treatment of patients with eGFr mutated nsClC
by: S V Orlov
Published: (2013-12-01)

Response of Erlotinib in Lung Adenocarcinoma Harboring EGFR Sensitive Mutation in Cerebrospinal Fluid: Case Report
by: Xiaoyan LI, et al.
Published: (2016-01-01)

Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
by: Debby D Wang, et al.
Published: (2015-01-01)

Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer
by: Dong Ha Kim, et al.
Published: (2018-12-01)

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?
by: Paola Ulivi, et al.
Published: (2014-12-01)

The Journey of an EGFR-Mutant Lung Adenocarcinoma through Erlotinib, Osimertinib and ABCP Immunotherapy Regimens: Sensitivity and Resistance
by: Albina Kibirova, et al.
Published: (2019-10-01)

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
by: William Pao, et al.
Published: (2005-03-01)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
by: Katsuhiro Yoshimura, MD, et al.
Published: (2017-01-01)

Erlotinib or Chemotherapy in Second-Line or Later Treatment of Tumor EGFR Wild-Type Pulmonary Adenocarcinoma Patients
by: Yuh-Min Chen, et al.
Published: (2015-03-01)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
by: Lin-Peng Zheng, et al.
Published: (2018-11-01)

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non–Small Cell Lung Cancer Cells
by: Yasemin Saygideğer-Kont, et al.
Published: (2016-02-01)

Rolle von KRAS und EGFR Expression bei Erlotinib behandelten Patienten mit fortgeschrittenem Pankreaskarzinom
by: Egg, Rosalind
Published: (2014)

Erlotinib: um anti-EGFR com utilidade terapêutica no carcinoma pulmonar de não pequenas células
by: Renato Sotto-Mayor
Published: (2008-10-01)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

The role of MYD88-dependent receptors in the anti-tumor efficacy of the EGFR inhibitor Erlotinib in head and neck cancer
by: Koch, Adam Taylor
Published: (2014)

Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
by: Tatsuro Fukuhara, et al.
Published: (2020-07-01)

A lung adenocarcinoma patient with EGFR mutation in exon 18 and ALK-rearrangement who treated with erlotinib and crizotinib
by: Mehmet Artaç, et al.
Published: (2018-08-01)

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature
by: Kishan Soni, et al.
Published: (2020-07-01)

Real-time molecular optical micro-imaging of EGFR mutations using a fluorescent erlotinib based tracer
by: Maxime Patout, et al.
Published: (2019-01-01)

Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
by: Lindsey Enewold, et al.
Published: (2016-01-01)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
by: Walleser S, et al.
Published: (2012-09-01)

Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation
by: Liu J, et al.
Published: (2016-02-01)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
by: Karachaliou N, et al.
Published: (2014-11-01)

The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy
by: Demiray A, et al.
Published: (2018-12-01)

Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma
by: Chenwei Wang, et al.
Published: (2021-03-01)

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment
by: Shihui Bao, et al.
Published: (2021-03-01)

The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment
by: Christina Demuth, et al.
Published: (2018-02-01)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
by: Bin Zou, et al.
Published: (2018-03-01)

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
by: Deborah Ayeni, et al.
Published: (2019-07-01)

Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
by: Genovefa Polychronidou, et al.
Published: (2013-03-01)

The Cost-effectiveness Analysis of Gefitinib or Erlotinib in the Treatment of  Advanced EGFR Mutant Non-small Cell Lung Cancer Patients
by: Yuxiang MA, et al.
Published: (2013-04-01)

Erlotinib Promotes Ligand-Induced EGFR Degradation in 3D but Not 2D Cultures of Pancreatic Ductal Adenocarcinoma Cells
by: Nausika Betriu, et al.
Published: (2021-09-01)